Global Tuberculosis Report (2023) https://www.who.int/publications-detail-redirect/9789240083851 (Accessed on 6th November, 2023)
WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. https://www.who.int/publications/i/item/9789240048126 (Accessed on 6th November, 2023)
Frieden T (2004) What is intermittent treatment and what is the scientific basis for intermittency? In: Frieden T (ed) Toman’s tuberculosis: case detection, treatment, and monitoring—questions and answers, 2nd edn. World Health Organization, Geneva, Switzerland, pp 130–138. Publication No. WHO/HTM/TB/2004.334
Feleke BE, Alene GD, Feleke TE, Motebaynore Y, Biadglegne F (2018) Clinical response of tuberculosis patients, a prospective cohort study. PLoS ONE 13(1):e0190207. https://doi.org/10.1371/journal.pone.0190207
Article CAS PubMed PubMed Central Google Scholar
Heysell SK, Moore JL, Keller SJ, Houpt ER (2010) Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16(10):1546–1553. https://doi.org/10.3201/eid1610.100374
Article PubMed PubMed Central Google Scholar
Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER (2013) Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat 2013:129723. https://doi.org/10.1155/2013/129723
Article CAS PubMed PubMed Central Google Scholar
Peloquin CA (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169–2183. https://doi.org/10.2165/00003495-200262150-00001
Article CAS PubMed Google Scholar
Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis. https://iris.who.int/bitstream/handle/10665/260440/WHO-CDS-TB-2018.6-eng.pdf (Accessed on 6th November, 2023)
Märtson AG, Burch G, Ghimire S, Alffenaar JC, Peloquin CA (2021) Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol 17(1):23–39. https://doi.org/10.1080/17425255.2021.1836158
Article CAS PubMed Google Scholar
Falzon D, Jaramillo E, Gilpin C, Weyer K (2018) The role of novel approaches and new findings in the pharmacology of tuberculosis medicines in improving treatment outcomes. Clin Infect Dis 67:S365–S367. https://doi.org/10.1093/cid/ciy710
Article CAS PubMed PubMed Central Google Scholar
Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF et al (2018) Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis. Antimicrob Agents Chemother 62:e00636-e718. https://doi.org/10.1128/AAC.00636-18
Article CAS PubMed PubMed Central Google Scholar
Via LE, England K, Weiner DM, Schimel D, Zimmerman MD, Dayao E et al (2015) A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother 59:4181–4189. https://doi.org/10.1128/AAC.00115-15
Article CAS PubMed PubMed Central Google Scholar
Daskapan A, de Lange WC, Akkerman OW, Kosterink JG, van der Werf TS, Stienstra Y, Alffenaar JW (2015) The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 45(2):569–571. https://doi.org/10.1183/09031936.00142614
Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D (2015) Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 61(Suppl 1):S18-24. https://doi.org/10.1093/cid/civ426
Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T (2013) Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208(9):1464–1473. https://doi.org/10.1093/infdis/jit352
Article CAS PubMed PubMed Central Google Scholar
Gonzalez FJ, Nebert DW (1990) Evolution of the P450 gene superfamily: animal-plant ‘warfare’, molecular drive and human genetic differences in drug oxidation. Trends Genet 6:182–186. https://doi.org/10.1016/0168-9525(90)90174-5
Article CAS PubMed Google Scholar
Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I et al (1997) Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 127:289–293. https://doi.org/10.7326/0003-4819-127-4-199708150-00006
Article CAS PubMed Google Scholar
Peloquin CA, MacPhee AA, Berning SE (1993) Malabsorption of antimycobacterial medications. N Engl J Med 329(15):1122–1123. https://doi.org/10.1056/NEJM199310073291513
Article CAS PubMed Google Scholar
Berning SE, Huitt GA, Iseman MD, Peloquin CA (1992) Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 327:1817–1818. https://doi.org/10.1056/NEJM199212173272514
Article CAS PubMed Google Scholar
Gordon SM, Horsburgh CR Jr, Peloquin CA, Havlik JA Jr, Metchock B, Heifets L et al (1993) Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 168:1559–1562. https://doi.org/10.1093/infdis/168.6.1559
Article CAS PubMed Google Scholar
Barakat MT, Scott J, Hughes JM, Walport M, Calam J, Friedland JS et al (1996) Grand Rounds-Hammersmith Hospital. Persistent fever in pulmonary tuberculosis BMJ 313(7071):1543–1545
Dieterlen P, Cassereau H, Lestradet H (1986) Malabsorption permanente de la rifampicine chez un diabétique atteint d’une maladie coeliaque [Permanent malabsorption of rifampicin in a diabetic with celiac disease]. Arch Fr Pediatr 43(6):421–422
Polosa K, Murphy KJR, Krishnaswamy K (1984) Rifampicin kinetics in undernutrition. Br J Cin Pharmacol 17:481–484. https://doi.org/10.1111/j.1365-2125.1984.tb02377.x
Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH et al (2006) Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43(7):848–854. https://doi.org/10.1086/507543
Article CAS PubMed Google Scholar
Gwilt PR, Nahhas RR, Tracewell WG (1991) The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmaco 20(6):477–490. https://doi.org/10.2165/00003088-199120060-00004
Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A et al (2005) Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40(10):1481–91. https://doi.org/10.1086/429321
Article CAS PubMed Google Scholar
Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D (2012) Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection. J Int Assoc Physicians AIDS Care (Chic) 11(5):273–276. https://doi.org/10.1177/1545109712454454
Mtabho CM, Semvua HH, van den Boogaard J, Irongo CF, Boeree MJ, Colbers A et al (2019) Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother 74(12):3537–3545. https://doi.org/10.1093/jac/dkz368
Article CAS PubMed PubMed Central Google Scholar
Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW (2019) Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. Eur Respir J 54(3):1900373. https://doi.org/10.1183/13993003.00373-2019
Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL et al (2015) Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. Diabetes 64(4):1459–1469. https://doi.org/10.2337/db14-0228
Article CAS PubMed Google Scholar
Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S (2017) Early interventions
留言 (0)